AstraZeneca's Brilique Approved In The EU
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca's antiplatelet agent Brilique/Brilinta receives its first approval, but pricing negotiations will delay launch in most countries.
You may also be interested in...
Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment
AstraZeneca's clot buster could benefit certain patients with Acute Coronary Syndromes, Germany's health technology assessors conclude.
Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment
AstraZeneca's clot buster could benefit certain patients with Acute Coronary Syndromes, Germany's health technology assessors conclude.
AstraZeneca's Brilique Cleared In NICE's Initial Appraisal
The U.K.'s cost regulator, NICE, clears AstraZeneca's antiplatelet drug ticagrelor for use in the National Health Service in a preliminary assessment.